Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lorus Therapeutics and Genentech, a member of the Roche Group, have entered into a global intellectual property licensing agreement for IL-17E in cancer.
Subscribe to our email newsletter
Lorus has discovered IL-17E (also known as IL-25) cytokine that plays a vital role in inflammation and has potent anticancer properties.
Lorus president and CEO Aiping Young said the company’s scientists have discovered the anticancer properties of IL-17E and have patents pending for the use of IL-17E in cancer in the major world markets.
"IL-17E represents a unique immunotherapeutic approach to the treatment of some of the most important cancers, and preclinical data to date shows excellent efficacy with low toxicity; properties that we plan to demonstrate in the clinic in the near future," Young added.
IL-17E was indentified to have anticancer properties against solid tumors, such as human melanoma, pancreatic, colon, lung, ovarian and breast tumour models with low toxicity.